Effects of pre-medication and warming device on systolic (SAP), diastolic (DAP) and mean (MAP) arterial pressures in dogs following pre-medication, induction and inhalant anesthesi... by Jacob P. Rastas (20642173)

Subjects:

Change in rectal temperature following pre-medication, induction and inhalant anesthesia. by Jacob P. Rastas (20642173)

Subjects:

Effects of pre-medication and warming device on heart rate (HR) assessed by pulse oximetry in dogs following pre-medication, induction and inhalant anesthesia. by Jacob P. Rastas (20642173)

Subjects:

S1 File - by Jacob P. Rastas (20642173)

Subjects:

Times to tracheal extubation, sternal recumbency and standing (minutes) following inhalant anesthesia and final rectal temperatures (°C) in each premedication-treatment group. by Jacob P. Rastas (20642173)

Subjects:

AVAcore placement. by Jacob P. Rastas (20642173)

Subjects:

General characteristics of study subjects. by Soo-Hee Hwang (17767519)

“…COVID-19 did not affect inpatient mortality (p = 0.9608), but in-hospital mortality decreased from 12% to 7% in the medical aid group.</p><p>Conclusion</p><p>Overall, we found that COVID-19 had an impact on admission rates of patients with AMI but did not have a significant impact on in-hospital mortality. …”

Socio-demographic and medical characteristics of patients with liver cancer. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. by Ayana Ablayeva (22103708)

Subjects:

Association between socio-demographic and medical parameters and all-cause mortality rates of liver cancer between 2014 and 2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and stage-specific incidence rate of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Regional and temporal burden of liver cancer in Kazakhstan (2014–2023). by Ayana Ablayeva (22103708)

Subjects:

CTL response following combination therapy with NDV. by Hedieh Zargaran (21410233)

Regional differences in percentage changes of N07BA drug prescribing rates during the pandemic. by Dainty Ei (22265317)

Subjects:

Hypnotic and sedative (N05C) prescribing changes from 2014 to 2022. by Dainty Ei (22265317)

Subjects: